tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Toxocariasis D014120 3 associated lipids
Translocation, Genetic D014178 20 associated lipids
Tremor D014202 15 associated lipids
Trichomonas Infections D014245 3 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Trypanosomiasis D014352 5 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ulcer D014456 16 associated lipids
Uremia D014511 33 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urination Disorders D014555 9 associated lipids
Urticaria D014581 13 associated lipids
Uveitis D014605 14 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Vascular Diseases D014652 16 associated lipids
Vasculitis D014657 14 associated lipids
Venous Insufficiency D014689 2 associated lipids
Viremia D014766 4 associated lipids
Vision Disorders D014786 10 associated lipids
Vitiligo D014820 2 associated lipids
Vomiting D014839 21 associated lipids
West Nile Fever D014901 1 associated lipids
Wounds, Stab D014951 3 associated lipids
Dementia, Vascular D015140 7 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Discitis D015299 2 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Scleritis D015423 3 associated lipids
Reperfusion Injury D015427 65 associated lipids
Weight Gain D015430 101 associated lipids
Weight Loss D015431 56 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Histiocytosis D015614 2 associated lipids
HIV Infections D015658 20 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Granuloma Annulare D016460 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Fungemia D016469 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Foot Ulcer D016523 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Critical Illness D016638 13 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Liver Failure D017093 5 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Polymyositis D017285 1 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Hyperpigmentation D017495 11 associated lipids
Hypopigmentation D017496 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Porokeratosis D017499 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Kakefuda T et al. Nitrosyl hemoglobin detected by near-infrared spectroscopy in rat liver allografts. 1999 Transpl. Int. pmid:10551995
Mizuta K et al. Influence of tacrolimus on bile acid and lipid composition in continuously drained bile using a rat model. Comparative study with cyclosporine. 1999 Transpl. Int. pmid:10551996
Reichert TE et al. The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines. 1999 Br. J. Cancer pmid:10555752
Gremillion RB et al. Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. 1999 J. Rheumatol. pmid:10555886
Myers JN et al. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome. 1999 J. Heart Lung Transplant. pmid:10561115
Müschen A et al. Differential IL-10 receptor gene expression in acute versus chronic atopic eczema. Modulation by immunosuppressive drugs and cytokines in normal cultured keratinocytes. 1999 Inflamm. Res. pmid:10563471
Fansa H et al. [Stimulation of Schwann cell growth and axon regeneration of peripheral nerves by the immunosuppressive drug FK 506]. 1999 Handchir Mikrochir Plast Chir pmid:10566134
Shaw LM et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. 1999 Clin Ther pmid:10566561
Asai A et al. High level calcineurin activity predisposes neuronal cells to apoptosis. 1999 J. Biol. Chem. pmid:10567426
Fujiki M et al. Role of T cells in bronchoalveolar space in the development of interstitial pneumonia induced by superantigen in autoimmune-prone mice. 1999 Am. J. Respir. Cell Mol. Biol. pmid:10572064
Shiratori T et al. [Immunosuppressive treatment of ulcerative colitis]. 1999 Nippon Rinsho pmid:10572417
Burke GW et al. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. 1999 Transplantation pmid:10573073
Young AL et al. Allo-limbal transplantation in patients with limbal stem cell deficiency. 1999 Br J Ophthalmol pmid:10574823
Rao SK et al. Limbal allografting using FK-506. 1999 Br J Ophthalmol pmid:10574824
Zhang Y et al. Immunosuppressant FK506 activates NF-kappaB through the proteasome-mediated degradation of IkappaBalpha. Requirement for Ikappabalpha n-terminal phosphorylation but not ubiquitination sites. 1999 J. Biol. Chem. pmid:10574930
Undre NA et al. Pharmacokinetics of tacrolimus: clinically relevant aspects. 1999 Transplant. Proc. pmid:10576037
Mayer AD Four-year follow-up of the European Tacrolimus Multicenter Renal Study. 1999 Transplant. Proc. pmid:10576038
Jordan ML et al. Tacrolimus-based immunosuppression in pediatric renal transplantation. 1999 Transplant. Proc. pmid:10576039
Kliem V et al. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation. 1999 Transplant. Proc. pmid:10576041
Friemann S et al. Conversion to tacrolimus in hyperlipidemic patients. 1999 Transplant. Proc. pmid:10576042
Kohnle M et al. Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia. 1999 Transplant. Proc. pmid:10576043
van Hooff JP et al. Tacrolimus and glucose metabolism. 1999 Transplant. Proc. pmid:10576044
Soriano S et al. Single-center experience with initial intravenous dosing of tacrolimus after kidney transplantation. 1999 Transplant. Proc. pmid:10576045
van Hooff JP et al. Dosing and management guidelines for tacrolimus in renal transplant patients. 1999 Transplant. Proc. pmid:10576046
Oliveira DB and Chang R Report of the first 118 tacrolimus-treated patients at St George's Hospital, London. 1999 Transplant. Proc. pmid:10576047
Jurewicz WA Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. 1999 Transplant. Proc. pmid:10576048
Forsythe J Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group. 1999 Transplant. Proc. pmid:10576049
Squifflet JP et al. The Benelux experience with the combination of tacrolimus and mycophenolate mofetil. 1999 Transplant. Proc. pmid:10576050
Morales JM et al. Tacrolimus, mycophenolate mofetil and corticosteroids as primary immunosuppression after renal transplantation at the Hospital 12 de Octubre, Madrid. 1999 Transplant. Proc. pmid:10576051
Jordan ML et al. Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-up. 1999 Transplant. Proc. pmid:10576052
Woodle ES et al. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience. 1999 Transplant. Proc. pmid:10576053
Vanrenterghem Y Vascular rejection with tacrolimus and potential long-term graft outcome. 1999 Transplant. Proc. pmid:10576054
Villaverde V et al. Leg bone pain syndrome in a kidney transplant patient treated with tacrolimus (FK506) 1999 Ann. Rheum. Dis. pmid:10577370
Przepiorka D et al. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. 1999 Bone Marrow Transplant. pmid:10578154
Watanabe Y et al. The expression of nonmuscle myosin heavy chain in rat renal transplantation. 1999 Transplant. Proc. pmid:10578260
Fukushima N et al. Role of endothelial apoptosis in delayed xenograft rejection in pig-to-baboon cardiac transplantation. 1999 Transplant. Proc. pmid:10578268
Moffatt SD and Metcalfe SM FK 506 versus cyclosporine in combination with anti-CD4/CD8 monoclonal antibodies. 1999 Transplant. Proc. pmid:10578271
Sawai T et al. A successful induction of tolerance by perioperative intrathymic injection in rat "high-responder" heart transplantation. 1999 Transplant. Proc. pmid:10578275
Uchida H et al. Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile. 1999 Transplant. Proc. pmid:10578276
Moffatt SD et al. Comparative efficacy of liposomal FK 506 with FK 506 (tacrolimus) with and without anti-CD4/CD8 monoclonal antibodies. 1999 Transplant. Proc. pmid:10578277
Hampel G et al. Different effects of cyclosporine and tacrolimus on the activation of mesangial metalloproteinases and their inhibitors. 1999 Transplant. Proc. pmid:10578279
Ishibashi M et al. Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period. 1999 Transplant. Proc. pmid:10578281
Tojimbara T et al. Oral vs intravenous tacrolimus-based induction therapy in renal transplantation. 1999 Transplant. Proc. pmid:10578282
Hairhara Y et al. Effect of fluconazole on blood levels of tacrolimus. 1999 Transplant. Proc. pmid:10578284
Tamura A et al. Combination effect of tacrolimus and FTY720 in liver transplantation in rats. 1999 Transplant. Proc. pmid:10578290
Kita J et al. Effects of tacrolimus on small and large bowel anastomoses in the rat. 1999 Transplant. Proc. pmid:10578292
Azuma T et al. Study of graft-infiltrating cells in the rat small bowel allograft using low-dose FK 506. 1999 Transplant. Proc. pmid:10578293
Antoniou EA et al. Effect of donor-specific transfusion in combination with FK 506 in rat cardiac allotransplantation. 1999 Transplant. Proc. pmid:10578296
Uchida H et al. Experimental intestinal transplantation using mouse fetal intestine in the rat: combination effect of FK 506 with cyclophosphamide. 1999 Transplant. Proc. pmid:10578297
Manu MA et al. Tacrolimus rescue for resistant rejection, chronic rejection, and immunoglobulin A nephropathy of renal allografts under primary cyclosporine A immunosuppression. 1999 Transplant. Proc. pmid:10578313